The model's full reasoning — Q4 2021 call → NOWe need to determine if management describes an identifiable piece of new business activity that has already started contributing partway through the reported period or is starting right now, and makes clear that the reported results captured only a partial, early slice of it, with the fuller run-rate arriving over the next few quarters as a matter of timing. Let's examine the transcript. The call is Q4 2021 earnings. Management discusses several things: HETLIOZ, Fanapt, tradipitant, etc. Key points: - HETLIOZ: They mention strong interest, but payer denials led to net decline. They discuss efforts to resolve payer challenges, particularly with Medicaid. They mention that they have made progress in the past quarter with state Medicaid programs, and that 10 states have revised criteria. They also mention that they are developing strategies for Medicare and commercial plans. However, this is about resolving payer challenges, not about a new business activity that has started contributing. It's about overcoming obstacles to existing business. - HETLIOZ for Smith-Magenis Syndrome (SMS): They launched HETLIOZ and HETLIOZ LQ for SMS. More than 50 patients with SMS are on treatment and more are awaiting payer approval. They are working with advocacy and DTC campaigns. This is a new indication launch. The launch has started, with 50 patients on treatment. But is this described as a partial early slice? They say "More than 50 patients with SMS are currently on treatment and more are awaiting payer approval." That suggests it's early, but they don't explicitly say that the reported results captured only a fraction of the potential. They also mention that they are working to increase awareness. However, the revenue from SMS is likely small relative to overall. They don't quantify the contribution. They also mention that payer reception for SMS has been more positive. But the question is whether management describes this as a new contributor that is already live and will ramp up over the next few quarters as a matter of timing. They do say "We are in the early stages of commercial launch for HETLIOZ in SMS" and that they expect growth tied to the continued launch. In the guidance, they say the upper end of HETLIOZ net product sales guidance assumes growth tied to the continued launch of HETLIOZ in SMS. So they are treating it as a contributor that is ramping.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| GPRE | Green Plains Inc. | Q4 2023 | 2024-02-07 | F |
| TEL | TE Connectivity Ltd. | Q4 2023 | 2023-11-01 | B |
| AFL | Aflac Incorporated | Q2 2023 | 2023-08-02 | C+ |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| WHF | WhiteHorse Finance | Q1 2022 | 2022-05-10 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| MAS | Masco Corporation | Q3 2018 | 2018-10-30 | C |
| CUBI | Customers Bancorp, Inc. | Q3 2018 | 2018-10-26 | C+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| ATI | Allegheny Technologies Incorporated | Q1 2018 | 2018-04-24 | B |
| ACHC | Acadia Healthcare Company, Inc. | Q4 2017 | 2018-02-22 | C+ |
| HTLF | Heartland Financial USA, Inc. | Q3 2017 | 2017-10-30 | B+ |
| MXL | MaxLinear, Inc. | Q2 2017 | 2017-08-08 | C |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| LEA | Lear Corporation | Q2 2017 | 2017-07-26 | B+ |
| DAN | Dana Incorporated | Q1 2017 | 2017-05-02 | B |
| SHOO | Steven Madden, Ltd. | Q1 2017 | 2017-04-21 | C |
| PDCO | Patterson Companies, Inc. | Q3 2017 | 2017-02-23 | C |
| WTS | Watts Water Technologies, Inc. | Q4 2016 | 2017-02-10 | B |
SHOO · Q1 2017 → YESThe question is about whether management describes a new business activity that has already started contributing partway through the reported period or is starting now, and that the reported results o...YES The transcript describes the Schwartz & Benjamin acquisition as a new contributor that began delivering sales in the reported Q1 period ($14 million, slightly above plan), with the results capturing only its early partial slice. Management explicitly notes that the full-quarter impact will arrive in subsequent quarters (dragging gross margin more going forward), 2017 will be breakeven-to-EPS, and meaningful profit contribution starts in 2018—making the fuller run-rate a pure timing matter of integration and ramp rather than any further winning. This meets all three criteria. (Madden NYC and SM Europe are also new launches/JVs with early/modest contributions and growth ahead, but Schwartz & Benjamin is the clearest fit for the exact timing story.) NO for the other items because they are either not yet live (China JV), not described as partial/early-slice (SM Europe international growth), or not framed as timing-driven ramp (Madden NYC modest contribution is positive but 2018+ profit is more about execution than pure timing). The answer is YES.
AFL · Q2 2023 → YESThe question is about whether management describes a new business activity that has already started contributing partway through the reported period or is starting now, and that the reported results o...YES The transcript describes the WINGS cancer insurance product launch in Japan Post (early April, during Q2) as a new, nameable contributor that began transacting mid-period. Management explicitly states it was the "majority contributor" to the 60% cancer sales increase in Q2 versus 2022, 26.6% overall sales premium growth, and notes the reported results captured only an early slice because "right when you launch the product, you'll have an immediate jump in sales in the early months followed by a calming down" with "still much more runway...
PDCO · Q3 2017 → YESThe question is about whether management describes a new business activity that has already started contributing partway through the reported period or is starting now, and that the reported results o...YES The transcript describes Heartland Dental as a new customer relationship that began contributing in January (during the reported Q3 period), with the rollout completed on schedule and the business now "getting close to being fully operational." Management explicitly notes that this was "not a significant contributor to consumable sales in the third quarter" — confirming the reported results captured only a partial, early slice — while highlighting the "outstanding start" and excitement for further growth as the relationship scales.